Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors

Solid tumors remain a major challenge for targeted therapeutic intervention strategies such as antibody-drug conjugates and immunotherapy. At a minimum, clear and actionable solid tumor targets have to comply with the key biological requirement of being differentially over-expressed in solid tumors...

Full description

Saved in:
Bibliographic Details
Published inCells (Basel, Switzerland) Vol. 9; no. 4; p. 818
Main Authors Khazamipour, Nastaran, Al-Nakouzi, Nader, Oo, Htoo Zarni, Ørum-Madsen, Maj, Steino, Anne, Sorensen, Poul H, Daugaard, Mads
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 28.03.2020
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Solid tumors remain a major challenge for targeted therapeutic intervention strategies such as antibody-drug conjugates and immunotherapy. At a minimum, clear and actionable solid tumor targets have to comply with the key biological requirement of being differentially over-expressed in solid tumors and metastasis, in contrast to healthy organs. Oncofetal chondroitin sulfate is a cancer-specific secondary glycosaminoglycan modification to proteoglycans expressed in a variety of solid tumors and metastasis. Normally, this modification is found to be exclusively expressed in the placenta, where it is thought to facilitate normal placental implantation during pregnancy. Informed by this biology, oncofetal chondroitin sulfate is currently under investigation as a broad and specific target in solid tumors. Here, we discuss oncofetal chondroitin sulfate as a potential therapeutic target in childhood solid tumors in the context of current knowhow obtained over the past five years in adult cancers.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2073-4409
2073-4409
DOI:10.3390/cells9040818